FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Introduction and Objectives: To estimate possibilities of use of long term neuroblocker - Botulotoxine type A (BoNTA) (BOTOX®) at patients with an Overactive Bladder resistant to anticholinergics therapy.
Materials: Under supervision there were 15 patients, 11 women and 4 men (middle age: 56 years, a range: 45-67), with the diagnosis a Overactive Bladder by which it has been injected on 300 UI BTX type A in submucose of a posterior wall of a bladder. Efficiency was estimated according to stationary urodynamic monitoring, and also on changes of questionnaires ICS. Average duration of supervision has made 4 months (a range: 2-7 months).
Results and Discussion: The analysis of results of the treatment was estimated according to stationary urodynamic monitoring, and also on changes of questionnaires ICS. Improvement of the general condition have noted 12 (80,0%) patients (ICS). The best results are noted at patients with kept bladder function, at 8 (53,3%) patients are noted considerable reduction of iritative symptoms, on the average to 76%. No adverse effects have been registered.
Conclusions: Application of BoNTA at patients with OVB, can be regarded as effective and safe therapy. Introduction of BoNTA in algorithm of treatment of patients with OVB is a perspective and necessary modern method in an arsenal of urologists.
KEYWORDS: Botulotoxin type A, BoNTA, overactive bladder, OVB